Stem Cells International / 2015 / Article / Fig 6

Research Article

Multiple Myeloma Patients at Various Cytogenetic Risks Benefit Differently from Autologous Stem Cell Transplantation as a Consolidation Therapy

Figure 6

Comparison of OS in the patients of ASCT group and non-ASCT group in the intermediate-risk subgroup. The median OS was 54 versus 42.1 months with no significant difference ().